Unaudited Condensed Interim Consolidated Financial Statements
For the Six Months Ended June 30, 2022 and 2021
(Expressed in Canadian dollars, unless otherwise noted)

# NOTICE OF DISCLOSURE OF NON-AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Pursuant to National-Instrument 51-102, Part 4, subsection 4.3(3)(a) issued by the Canadian Securities administrators, if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor. The accompanying unaudited condensed interim consolidated financial statements of the Company for the interim period ended June 30, 2022, have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board applicable to the preparation of interim financial statements including International Accounting Standard 34- Interim Financial Reporting and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements

Unaudited Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars)

|   | June 31, 2022          | December 31,<br>2021   |
|---|------------------------|------------------------|
|   | \$                     | \$                     |
| Assets  |                        |                        |
| Current   |                        |                        |
| Cash  | 803,245                | 3,886,851              |
| Accounts receivable (Note 5)  | 178,935                | 153,291                |
| Prepaid expenses  | 89,649                 | 125,635                |
|   | 1,071,829              | 4,165,777              |
| Lease deposits  | 130,368                | 161,392                |
| Property and equipment (Note 6)                                       | 401,340                | 407,294                |
| Right-of-use assets (Note 10)   | 5,359,039              | 5,221,164              |
| Goodwill (Note 8)   | 1,063,630              | 1,063,510              |
| Intangible assets (Note 7)  | 814,377                | 725,650                |
|   | 8,840,583              | 11,744,787             |
| Liabilities Current Accounts payable and accrued liabilities (Note 9) | 415,083                | 686,674                |
| Acquisition consideration payable (Note 4) Debenture Interest Payable | 24,249<br>57,505       | 1,916,556              |
| Lease obligations (Note 10)   | 861,539                | 679,507                |
|   | 1,358,376              | 3,282,737              |
|   |                        |                        |
| Long term lease obligations (Note 10)                                 | 5,029,962              | 4,805,944              |
| Long term share consideration payable (Note 4)                        | 21,669                 | -                      |
| Debenture (Note 12)   | 2,989,940              | <u>-</u>               |
|   | 8,041,571              | 8,088,681              |
| Shareholders' Equity (Deficiency)                                     |                        |                        |
| Share capital (Note 14)   | 13,369,210             | 13,369,210             |
| Share options and warrants  | 4,161,635              | 3,198,819              |
| Deficit   | (17,439,215)           | (12,613,135)           |
| Accumulated other comprehensive loss                                  | (422,526)              | (130,481)              |
| Non controlling interest (Note 44)                                    | (330,896)              | 3,824,413              |
| Non-controlling interest (Note 11)                                    | (228,468)<br>(559,364) | (168,307)<br>3,656,106 |
|   | 8,840,583              | 11,744,787             |
|   | 0,040,303              | 11,144,101             |

Nature of operations and going concern (Note 1) Contingency (Note 17) Subsequent event (Note 18)

Approved by the Board of Directors:

<u>"Kathryn Walker"</u> Kathryn Walker, Director and CEO <u>"Kevin Murray"</u> Kevin Murray, Director and CFO

Revitalist Lifestyle and Wellness Ltd.
Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Expressed in Canadian dollars)

|  | Three Months End June 30 |            | Six Months End June 30 |              |
|--|--------------------------|------------|------------------------|--------------|
|  | 2022                     | 2021       | 2022                   | 2021         |
| Revenue  |                          |            |                        |              |
| Patient services                                     | 1,354,379                | 372,046    | 2,435,920              | 521,031      |
|  |                          |            |                        |              |
| Expenses   |                          |            |                        |              |
| Accretion of share consideration payable (Note 4)    | -(27,368)                | 75,210     | 720                    | 111,580      |
| Advertising and promotion                            | 264,710                  | 47,012     | 526,533                | 56,278       |
| Amortization and depreciation (Notes 6 and 7)        | 41,924                   | 36,808     | 78,700                 | 99,486       |
| Amortization of right-of-use assets (Note 10)        | 316,339                  | 99,565     | 608,478                | 123,263      |
| Dues and subscriptions                               | 35,164                   | 7,666      | 57,040                 | 8,501        |
| Insurance  | 30,642                   | 15,558     | 58,173                 | 15,772       |
| Interest and bank charges                            | 96,478                   | 4,037      | 102,485                | 5,393        |
| Interest expense on lease liability (Note 10)        | 213,093                  | 74,071     | 430,402                | 91,761       |
| Meals and entertainment                              | 48                       | 1,457      | 2,781                  | 2,132        |
| Medication and supplies                              | 76,451                   | 77,644     | 194,658                | 81,699       |
| Office and administrative                            | 140,195                  | 126,504    | 291,776                | 144,614      |
| Professional fees                                    | 222,495                  | 91,677     | 286,654                | 139,430      |
| Revitaland Development                               | 37,881                   | <u>-</u>   | 150,403                | <del>-</del> |
| Salaries and Wages                                   | 1,810,477                | 740,688    | 4,111,864              | 970,841      |
| Share based compensation (Note 4)                    | 410,756                  | 68,953     | 962,816                | 101,535      |
| Utilities  | 59,079                   | 25,921     | 113,518                | 28,023       |
|  | 3,728,364                | 1,466,850  | 7,977,001              | 5,335,817    |
| Loss before other items                              | 2,373,985                | 1,120,725  | 5,541,081              | 4,842,809    |
| Foreign exchange                                     | -120                     | -22        | -120                   | 2,286        |
| Gain on convertible debenture derivative liability   | 654,721                  |            | 654,721                |              |
| Net loss for the year                                | 1,719,144                | 1,120,703  | 4,886,240              | 4,845,095    |
| Unrealized loss on translation to reporting currency | 203,919                  | 9,125      | 292,045                | 9125         |
| Comprehensive loss for the year                      | 1,923,063                | 1,129,828  | 5,178,285              | 4,854,220    |
| Net loss attributable to:                            |                          |            |                        |              |
| Shareholders of the Company                          | 1,703,993                | 3,716,625  | 4,826,080              | 4,846,453    |
| Non-controlling interests                            | 15,151                   | 1,120,703  | 60,160                 | 4,845,095    |
|  | 1,719,144                | 1,120,703  | 4,886,240              | 4,845,095    |
| Net comprehensive loss attributable to:              | , ,                      |            |                        |              |
| Shareholders of the Company                          | 1,800,746                | 1,120,703  | 5,009,979              | 9,125        |
| Non-controlling interests                            | 123,117                  | -          | 168,307                | -,           |
|  | 1,923,863                | 1,120,703  | 5,178,285              | 9,125        |
| Loss per share (basic and diluted)                   | 0.04                     | 0.03       | 0.09                   | 0.00         |
| Loss per sitate (basic and unded)                    | 0.04                     | 0.03       | 0.03                   | 0.00         |
| Weighted average number of common shares outstanding | 67,712,580               | 44,023,387 | 67,712,580             | 44,023,387   |

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Revitalist Lifestyle and Wellness Ltd.
Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Expressed in Canadian dollars)

|   | Common<br>Shares | Share<br>Capital | Share options and warrants | Deficit      | Non-<br>controlling<br>interest | Accumulated<br>Other<br>Comprehensive<br>Loss | Total Equity |
|---|------------------|------------------|----------------------------|--------------|---------------------------------|---|--------------|
| Balance, December 31, 2020              | 25,750,001       | _                | _                          | (4,731)      | _                               | _   | (4,731)      |
| Shares issued                           | 23,246,917       | 9,404,962        | -                          | -            | _                               | -   | 9,404,962    |
| Shares issuable on acquisition (Note 5) | 18,715,662       | 5,614,699        | -                          | -            | -                               | -   | 5,614,699    |
| Share issuance costs                    |                  | (557,936)        |                            |              |                                 |   | (557,936)    |
| Warrants Issued                         | -                | (1,092,515)      | 1,092,515                  | -            | -                               | -   | -            |
| Stock based compensation                |                  |                  | 2,106,304                  |              |                                 |   | 2,106,304    |
| Net loss for the period                 | -                | -                | -                          | (12,608,404) | (168,307)                       | -   | (12,776,711) |
| Translation adjustments                 |                  | -                | -                          | -            | -                               | (130,481)                                     | (130,481)    |
| Balance, December 31, 2021              | 67,120,580       | 13,369,210       | 3,198,819                  | (12,613,135) | (168,307)                       | (130,481)                                     | 3,656,106    |
| Balance, December 31, 2021              | 67,712,580       | 13,369,210       | 3,198,819                  | (12,613,135) | (168,307)                       | (130,481)                                     | 3,656,106    |
| Share based compensation                | -                | -                | 962,816                    | <u>-</u>     | -                               | -   | 962,816      |
| Net loss for the period                 | -                | -                | -                          | (5,480,801)) | (60,161)                        | -   | (5,540,962)  |
| Translation adjustments                 | -                | -                | -                          |              | -                               | (292,045)                                     | (292,045)    |
| Gain on Debenture                       |                  |                  |                            | 654,721      |                                 |   | 654,721      |
| Balance, June 30, 2022                  | 67,712,580       | 13,369,210       | 4,161,635                  | (17,439,215) | (228,468)                       | (422,526)                                     | (559,364)    |

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

# **Revitalist Lifestyle and Wellness Ltd.**Consolidated Statement of Cash Flows

(Expressed in Canadian dollars)

|   | Six months ended<br>June 30, 2022 | Six months ended<br>June 30, 2021 |
|---|-----------------------------------|-----------------------------------|
|   | \$                                | \$                                |
| Cash provided by (used in):                         |                                   |                                   |
| Operating activities                                | (4.000.000)                       | (2.704.200)                       |
| Net loss Add (deduct) items not affecting cash:     | (4,826,080)                       | (3,724,392)                       |
| Amortization of right-of-use assets                 | 316,339                           | -                                 |
| Amortization and depreciation                       | 78,700                            | 86,376                            |
| Foreign currency translation                        | (292,045)                         | 121                               |
| Interest expense on lease liability                 | 213,093                           | 54,176                            |
| Accretion of share consideration payable            | 21,669                            | · <u>-</u>                        |
| Share based compensation                            | 962,816                           | 32,582                            |
| Equity portion of debenture                         |                                   |                                   |
| Share based compensation on acquisition             | (654,721)                         | 3,383,532                         |
| Changes in non-cash working capital balances:       | • • •                             |                                   |
| Accounts receivable                                 | (25,644)                          | 1,253,885                         |
| Prepaid expenses                                    | 35,986                            | (399,113)                         |
| Accounts payable and accrued liabilities            | (251,753)                         | 27,505                            |
| Net cash (used in) provided by operating activities | (4,421,640)                       | 714,672                           |
| Investing activities:                               |                                   |                                   |
| Cash paid for purchase of intangible assets         | (120,926)                         | -                                 |
| Cash paid for purchase of property and equipment    | (40,369)                          | -                                 |
| Cash paid on Revitalist acquisition                 | (1,915,000)                       | (176,711)                         |
| Cash obtained on acquisition                        | -                                 | 352,417                           |
| Lease payments                                      | (261,356)                         | (33,827)                          |
| Lease deposits                                      | 31,024                            | -                                 |
| Net cash used in investing activities               | (2,306,627)                       | 141,879                           |
| Financing activities                                |                                   |                                   |
| Proceeds from issuance of share capital             | 3,644,661                         | 427,500                           |
| Net cash from financing activities                  | 3,644,661                         | 427,500                           |
|   | <b></b>                           |                                   |
| Net change in cash                                  | (3,083,606)                       | 1,284,051                         |
| Cash, beginning of period                           | 3,886,851                         | 1 204 054                         |
| Cash, end of period                                 | 803,245                           | 1,284,051                         |

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 1. NATURE OF OPERATIONS AND GOING CONCERN

Revitalist Lifestyle and Wellness Ltd. (formerly Dealpool Capital Corp.) (the "Company" or "Revitalist" or "Group") is a publicly listed company incorporated in the Province of British Columbia on July 6, 2018, under the Business Corporations Act of British Columbia. The Company's common shares are listed on the Canadian Securities Exchange under the symbol "CALM." The Company's registered records office is located at 3200 – 650 West Georgia Street, Vancouver, British Columbia, V6B 4P7 and its head office is located at 10608 Flickenger Lane, Knoxville, TN, 37922.

Revitalist is a mental health company enabling safe access to psychedelic medicine through a network of clinics located in the United States. Revitalist provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics.

These unaudited condensed interim consolidated financial statements comprise the financial statements of the Company, its legal subsidiaries, Ketamine Holdings Ltd. ("Ketamine Holdings"), Ketamine Holdings (USA) Ltd. ("Ketamine Holdings (USA)"), Revitalist, LLC ("Revitalist, LLC"), Revitaland Meta Tech Inc. ("Revitaland") and one ketamine clinic in the United States owned by statelicensed physicians and organized as professional medical corporations ("PCs").

These unaudited condensed interim financial statements have been prepared on the basis of accounting principles applicable to a going concern, which presumes that the Company will realize its assets and discharge its liabilities in the normal course of business for at least the next twelve months.

The Company will require additional financing in the next twelve months and has historically raised funds principally through the sale of securities. The Company expects it will continue to obtain funding; however, the timing and availability of additional financing will be determined largely by the performance of the Company and market conditions. There can be no assurance that the Company will be able to raise funds as they are required in the future. The Company has a cumulative deficit of \$17,439,215 and negative cash flow for the period from operations of \$4,421,640. These factors indicate the existence of a material uncertainty that casts significant doubt about the Company's ability to continue as a going concern.

These unaudited condensed interim financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis was not appropriate for These unaudited condensed interim financial statements, then adjustments would be necessary to reflect These unaudited condensed interim financial statements on a liquidation basis which could differ from accounting principles applicable to a going concern.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. At this point, the impact on the Company has been minimal. The Company continues to monitor the situation and is taking all necessary precautions in order to follow rules and best practices as set out by the federal and provincial governments.

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 2. BASIS OF PREPARATION

#### a) Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting. Accordingly, they do not include all the information and notes to the consolidated financial statements required by IFRS for complete financial statements and should be read in conjunction with the Company's most recent audited consolidated financial statements. In preparation of these condensed interim consolidated financial statements, the Company has consistently applied the same accounting policies disclosed in the Company's audited annual financial statements for the year ended December 31, 2021.

These unaudited condensed interim financial statements were authorized for issue by the Board of Directors on August 29,, 2022.

#### b) Basis of measurement

These unaudited condensed interim financial statements are a continuation of the consolidated financial statements of the Company and have been prepared on a historical cost basis except for certain financial instruments, which are measured at fair value.

The preparation of These unaudited condensed interim financial statements in compliance with IFRS requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

#### c) Basis of consolidation

These unaudited condensed interim financial statements comprise the financial statements of the Company, its legal subsidiaries and one PC, RVLWF, PLLC. Subsidiaries are those entities which the Company controls by having the power to govern the financial and operational policies of the entity. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a company's share capital. All intercompany transactions and balances have been eliminated. The Company controls the following entities:

|                           | Percentage ownership interes |      |
|---------------------------|------------------------------|------|
|                           | 2021                         | 2020 |
| KETAMINE HOLDINGS         | 100%                         | 0%   |
| KETAMINE HOLDINGS (USA)   | 100%                         | 0%   |
| REVITALIST, LLC           | 100%                         | 0%   |
| REVITALAND META TECH INC. | 60%                          | 0%   |

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 2. BASIS OF PREPARATION (cont'd)

#### d) Functional and presentation currency

The Group's presentation currency is the Canadian dollar. The functional currency of Revitalist, Ketamine Holdings, and Ketamine Holdings (USA) is the Canadian dollar. The functional currency of Revitalist, LLC, Revitaland and RVLWF, PLLC is the US dollar ("USD"). Foreign currency transactions are translated into the functional currency at the exchange rate as at the date of the transaction. At each statement of financial position date, monetary assets and liabilities in foreign currencies are translated using the period end foreign exchange rate. Nonmonetary assets and liabilities in foreign currencies are translated using the historical rate. All gains and losses on translation of these foreign currency transactions are included in profit and loss. The results and financial position of a subsidiary that has a functional currency different from the presentation currency are translated into the presentation currency as follows:

- i. Assets and liabilities are translated at the closing rate at the reporting date;
- ii. Income and expenses for each income statement are translated at average exchange rates for the period; and
- iii. All resulting exchange differences are recognized in other comprehensive income as cumulative translation adjustments.

On consolidation, exchange differences arising from the translation of the net investment in a foreign operation are taken to accumulated other comprehensive loss. When a foreign operation is sold, such exchange differences are recognized in profit or loss as part of the gain or loss on sale.

#### 3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies applied in these unaudited condensed consolidated interim financial statements are the same as those applied in the Company's annual audited consolidated financial statements as at and for the year ended December 31, 2021.

#### 4. ACQUISITIONS

Florida Acquisition

On January 11, 2022, Revitalist acquired 100% of the assets of a medical clinic located in Florida "Florida Acquisition". The purchase price for the Florida Acquisition was \$100,000 US dollars, with \$60,000 US dollars payable in cash on January 11, 2022, and \$40,000 US dollars payable in Common Shares of the Company in two equal instalments on January 11, 2023, and January 11, 2024.

The Florida Acquisition was accounted for as a business combination as the assets acquired and liabilities assumed constitute a business. The transaction was accounted for using the acquisition method of accounting whereby the assets acquired, and the liabilities assumed were recorded at their estimated fair value at the acquisition date. The Company has allocated 100% of the purchase price to customer lists. These provisional amounts may be adjusted during the measurement period, or additional assets may be recognized, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date.

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 4. ACQUISITIONS (cont'd)

The allocation of the components of total consideration to the assets acquired was as follows:

| Consideration                     | \$      |
|-----------------------------------|---------|
| Acquisition consideration payable | 42,291  |
| Cash consideration paid           | 74,976  |
|                                   | 117,267 |
|                                   |         |
| Assets acquired                   | \$      |
| Customer list                     | 117,267 |
| Total net assets acquired         | 117.267 |

The Company recorded accretion expense of \$1,003 during the period bringing the acquisition consideration payable to \$43,294 as at June 30, 2022. The discount rate used to determine the present value of the liability was 11.3% over a period of one year.

#### Revitalist Acquisition

On February 16, 2021, Ketamine Holdings (USA) entered into an agreement to acquire 100% of the membership interest of Revitalist, LLC (the "Revitalist Acquisition").

Consideration was payable as follows: \$150,000 USD cash on closing, and the remainder on or before June 30, 2022. The transaction closed on April 19, 2022.

The Revitalist Acquisition was accounted for as a business combination as the assets acquired and liabilities assumed constitute a business. The transaction was accounted for using the acquisition method of accounting whereby the assets acquired, and the liabilities assumed were recorded at their estimated fair value at the acquisition date. The Company applied various estimates and valuation techniques in order to measure the assets acquired and the liabilities assumed in the business combination.

The allocation of the components of total consideration to the net assets acquired was as follows:

| Consideration                            | \$        |
|--|-----------|
| Acquisition consideration payable        | 1,736,871 |
| Cash consideration paid                  | 190,170   |
|  | 1,927,041 |
| Net assets acquired                      | \$        |
| Cash                                     | 13,445    |
| Accounts receivable                      | 3,453     |
| Property and equipment                   | 89,195    |
| Right-of-use asset                       | 727,965   |
| Customer list                            | 322,000   |
| Brand and trademark                      | 460,000   |
| Goodwill                                 | 1,063,510 |
| Accounts payable and accrued liabilities | (24,562)  |
| Lease obligations                        | (727,965) |
| Total net assets acquired                | 1,927,041 |

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 4. ACQUISITIONS (cont'd)

The acquisition consideration payable was settled on April 19, 2022.

The resulting goodwill represents the sales and growth potential of Revitalist, LLC and will be deductible for tax purposes.

#### Ketamine Holdings Acquisition

On February 19, 2021, Revitalist acquired 100% of the outstanding shares of Ketamine Holdings and issued 18,715,662 common shares to the shareholders of Ketamine Holdings. The Acquisition does not constitute a business combination under IFRS 3 Business Combinations as Revitalist did not meet the definition of a business prior to the transaction. Accordingly, the Acquisition has been accounted for as an acquisition by Ketamine Holdings of the Company's net assets. In accordance with the principles of reverse take-over accounting, Ketamine Holdings will report the operations and its related historical comparatives as its continuing business.

The acquisition date fair value of the consideration was estimated based on the net asset value of the Company using the last financing price in Revitalist as follows:

|   | \$        |
|---|-----------|
| Consideration paid  |           |
| Common shares issued (18,715,662 common shares at \$0.30) | 5,614,699 |
|   |           |
| Assets (liabilities) acquired                             |           |
| Cash  | 352,417   |
| Prepaid expenses and deposits                             | 100,000   |
| Subscriptions receivable                                  | 1,781,791 |
| Accounts payable and accrued liabilities                  | (3,040)   |
| Net assets acquired                                       | 2,231,167 |
| Acquisition expense – share based compensation            | 3,383,532 |

The share-based compensation represents the services and knowledge related to the expertise that the Ketamine Holdings brings to the Company.

#### 5. ACCOUNTS RECEIVABLE

|                           | June 30, 2022 | December 31, 2021 |
|---------------------------|---------------|-------------------|
|                           | \$            | \$                |
| Trade receivables         | 87,922        | 85,957            |
| GST and taxes recoverable | 91,013        | 67,334            |
|                           | 178,935       | 153,291           |

Trade receivables relates to amounts receivable from patients/insurance for treatments completed at the clinics. No expected credit loss allowance was recorded for accounts receivable. No receivables were written off during the period.

**Revitalist Lifestyle and Wellness Ltd.**Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 6. PROPERTY AND EQUIPMENT

|                            | Furniture and Fixtures | Computer<br>Equipment and<br>Software | Leasehold<br>Improvements | Total       |
|----------------------------|------------------------|---------------------------------------|---------------------------|-------------|
|                            | \$                     | \$                                    | \$                        | Total<br>\$ |
| Cost                       | Ψ                      | Ψ                                     | Ψ                         | Ψ           |
| Balance, December 31, 2021 | 102,356                | 172,179                               | 181,165                   | 455,700     |
| Additions                  | 1,679                  | 19,488                                | 19,202                    | 40,369      |
| Balance, June 30, 2022     | 104,035                | 191,667                               | 200,367                   | 496,069     |
| Depreciation               |                        |                                       |                           |             |
| Balance, December 31, 2021 | 10,573                 | 12,494                                | 25,339                    | 48,406      |
| Additions                  | 14,999                 | 8,257                                 | 23,067                    | 46,323      |
| Balance, June 30, 2022     | 25,572                 | 20,751                                | 48,406                    | 94,729      |
| Balance, December 31, 2021 | 91,783                 | 159,685                               | 155,826                   | 407,294     |
| Balance, June 30, 2022     | 78,473                 | 170,916                               | 157,961                   | 401,340     |

#### 7. **INTANGIBLE ASSETS**

|                            | Brand and<br>Trademark | Customer List | Total   |
|----------------------------|------------------------|---------------|---------|
|                            | \$                     | \$            | \$      |
| Cost                       |                        |               |         |
| Balance, December 31, 2021 | 460,000                | 322,000       | 782,000 |
| Additions                  |                        | 120,926       | 120,926 |
| Balance, June 30, 2022     | 460,000                | 442,926       | 902,926 |
| Amortization               |                        |               |         |
| Balance, December 31, 2021 | -                      | 56,350        | 56,350  |
| Additions                  | -                      | 32,377        | 32,377  |
| Balance, June 30, 2022     | -                      | 88,727        | 88,727  |
| Balance, December 31, 2021 | 460,000                | 265,650       | 725,650 |
| Balance, June 30, 2022     | 460,000                | 354,377       | 814,377 |

#### **GOODWILL** 8.

|                            | Total     |
|----------------------------|-----------|
|                            | \$        |
| Cost                       |           |
| Balance, December 31, 2021 | 1,063,510 |
| Additions                  | 120       |
| Balance, June 30, 2022     | 1,063,630 |

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 9. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

|                        | 31-Mar-22 | 31-Dec-21 |
|------------------------|-----------|-----------|
|                        | \$        | \$        |
| Trade accounts payable | 219,674   | 54,381    |
| Accrued liabilities    | 46,200    | 298,924   |
| Payroll liabilities    | 149,209   | 333,369   |
|                        | 415,083   | 686,674   |

#### 10. RIGHT OF USE ASSET AND LEASE LIABILITY

|                            | Right of Use Asset |
|----------------------------|--------------------|
|                            | \$                 |
| Cost                       |                    |
| Balance, December 31, 2021 | 5,778,704          |
| Additions                  | 746,553            |
| Balance, June 30, 2022     | 6,525,057          |
| Depreciation               |                    |
| Balance, December 31, 2021 | (557,540)          |
| Additions                  | (608,478)          |
| Balance, June 30, 2022     | (1,166,018)        |
| Balance, December 31, 2021 | 5,221,164          |
| Balance, June 30, 2022     | 5,359,039          |

The Company's right-of-use assets consist of clinic premises and medical equipment leases.

The following is the continuity of lease liabilities, for the six months ended June 30, 2022:

|                                       | June 30, 2022 |
|---------------------------------------|---------------|
|                                       | \$            |
| Opening balance, December 31, 2021    | 5,485,451     |
| Additions                             | 746,553       |
| Lease payments                        | (770,905)     |
| Interest expense on lease liabilities | 430,402       |
|                                       | 5,891,501     |
| Current portion                       | 861,539       |
| Long-term portion                     | 5,029,962     |

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 10. RIGHT OF USE ASSET AND LEASE LIABILITY (cont'd)

|                                       | December 31, 2021 |
|---------------------------------------|-------------------|
|                                       | \$                |
| Opening balance, December 31, 2020    | -                 |
| Assumed at Acquisition                | 727,965           |
| Additions                             | 5,050,739         |
| Lease payments                        | (702,713)         |
| Interest expense on lease liabilities | 409,460           |
|                                       | 5,485,451         |
| Current portion                       | 679,507           |
| Long-term portion                     | 4,805,944         |

As at June 30, 2022, the minimum lease payments for the lease liabilities are as follows:

| Year ending:                                  | \$        |
|---|-----------|
| 2022  | 1,083,465 |
| 2023  | 1,746,342 |
| 2024  | 1,770,303 |
| 2025  | 1,762,737 |
| 2026  | 1,060,138 |
| 2027  | 245,873   |
| 2028-2032                                     | 1,106,532 |
|   | 8,775,390 |
| Less: Interest expense on lease liabilities   | 2,883,888 |
| Total present value of minimum lease payments | 5,891,502 |

When measuring lease obligations, the Company's incremental borrowing rate applied was 14.3% per annum.

#### 11. NON-CONTROLLING INTEREST

The non-controlling interest represents equity in Revitaland that is not attributable to the Company.

The following table represents the summarized financial information of Revitaland:

| Ownership interest: 60%                                       | 30-June -22 | 31-Dec-21 |
|---|-------------|-----------|
|   | \$          | \$        |
| Ourse at a sector   |             |           |
| Current assets  | -           | -         |
| Non-current assets  | -           | -         |
| Current liabilities   | -           | -         |
| Non-current liabilities                                       | 571,777     | 420,768   |
| Revenue for the year ended                                    | -           | -         |
| Net loss for the year ended                                   | 150,403     | 420,768   |
| Net loss attributable to non-controlling interest             | 228,468     | 168,307   |
|   |             |           |
| The net change in the non-controlling interest is as follows: |             |           |
|   |             | \$        |
| Balance, December 31, 2021                                    |             | 168,307   |
| Net loss attributable to non-controlling interest             |             | 60,161    |
| Balance, June 30, 2022  |             | 228,468   |

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 12. Debenture

On April 19, 2022, the company closed its first tranche of non-brokered private placement offering for aggregate gross proceeds to the Company of \$3,644,000 (the "Private Placement"). Pursuant to the Private Placement, the Company issued convertible note units (the "Units") at a subscription price of \$1,000 per Unit, each Unit composed of (i) \$1,000 in principal amount of unsecured convertible note of the Company (a "Note") and (ii) 3,500 detachable common share purchase warrants (each warrant, a "Warrant"). Each Note matures in 36 months from the date of issuance ("Maturity Date") and will accrue simple interest at 8% ("Interest") per annum, payable quarterly. Each Note, and any accrued but unpaid interest thereon, is convertible into common shares of the Company at a conversion price of \$0.15 at any time prior to the Maturity Date. Each Warrant will be exercisable at \$0.20 per share at any time until the date that is 24 months from the date of issuance ("Expiry Date"). In the event that, at any time after the date of issuance and before the Expiry Date, the 15 day trading volume weighted average price of the common shares of the Company on the Canadian Securities Exchange exceeds \$0.50, the Company is entitled to accelerate the expiry date of the Warrants to the date that is not less than 30 trading days following the date notice of such acceleration is delivered to Warrant holders. The convertible debentures are recognized as having two separate liability components. Firstly, the units which are recognized as a derivative liability and fair valued each reporting period, and secondly the convertible debenture liability, which is fair valued at the time of issue, and then accounted for at amortized cost and accreted to the face value over the life of the convertible debentures.

At inception, the Company recognized a deferred unrealized gain in the amount of \$654,721, which was the difference between the fair value of the combined liability and the proceeds received. The deferred unrealized gain has been recorded against the convertible debentures on the balance sheet and will be amortized over the life of the warrants on a straight-line basis. Any subsequent fair value changes will be recognized in the Statement of Income (Loss) and Comprehensive Income (Loss)

In accordance with IFRS 9 – Financial Instruments ("IFRS 9"), it has been determined that the respective convertible debentures are, for IFRS purposes, hybrid debt instruments which contain non-cash embedded derivative liabilities associated with the conversion features of the debentures into units. IFRS 9 further determines that the debenture is to be measured at amortized cost and the noncash embedded derivative is to be measured at fair value.

The convertible debentures and non-cash derivative liabilities have a combined carrying value of \$3,644,661, representing the discounted face value of the debentures of \$654,721 and the fair value of the non-cash embedded derivative liability of \$2,989,940.

#### 13. RELATED PARTY TRANSACTIONS AND BALANCES

#### Key management personnel compensation

Key management is composed of the Company's directors and executive officers. The Company incurred the following key management compensation charges during the six months ended June 30:

|                                       | 2022    | 2021   |
|---------------------------------------|---------|--------|
|                                       | \$      | \$     |
| Salaries, bonuses, fees, and benefits | 158,275 | 28,846 |
| Share based compensation              | 65,141  | 45,669 |
|                                       | 223,416 | 74,515 |

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 13. RELATED PARTY TRANSACTIONS AND BALANCES (cont'd)

During the six months ended June 30, the Company made the following lease payments to a company controlled by the CEO:

|                | 2022    | 2021   |
|----------------|---------|--------|
|                | \$      | \$     |
| Lease payments | 128,772 | 25,546 |
|                | 128,772 | 25,546 |

The Company had the following outstanding amounts owed to a related party as at:

|                  | June 30, 2022 | December 31, 2021 |
|------------------|---------------|-------------------|
|                  | \$            | \$                |
| Accounts payable | 11,007        | 5,291             |

#### 14. SHARE CAPITAL

#### **Authorized Share Capital**

The Company has an unlimited number of common shares without par value authorized for issuance. As at June 30, 2022, the Company had 67,712,580 (December 31, 2021 - 67,712,580) common shares issued and outstanding.

#### **Share Transactions**

On February 3, 2021, The Company closed a private placement and issued 5,700,000 common shares for proceeds of \$430,075.

On February 19, 2021, the Company issued 18,715,662 common shares per the transaction described in Note 4.

On July 14, 2021, the company closed a private placement for aggregate gross proceeds of \$5,594,887 through the issuance of 11,189,774 special warrants at a price of \$0.50 per special warrant. Each special warrant entitled the holder to receive one common share of the Company. The special warrants converted to common shares at the time the Company listed its shares for trading on the Canadian Securities Exchange on August 24, 2021.

On November 17, 2021, the Company closed a private placement for aggregate gross proceeds of \$3,000,000 through the issuance of 5,357,143 common share units. Each unit consisted of one common share and 1 common share purchase warrants with an exercise price of \$0.69 each. The fair market value of these warrants using the residual value method was \$ 964,286. The exclusive placement agent in the transaction received warrants with an exercise price of \$0.56 each ("Agent Warrants"). All warrants issued may be exercised over a period of 5 years. The fair value of the Agent Warrants granted during the period using the Black Scholes option pricing model was \$128,229. The following assumptions were used: exercise price of \$0, estimated volatility of 150% based on comparable companies, expected life of 5 years and a risk-free rate of 0.14%.

On November 19, 2021, the Company issued 1,000,000 common shares with a fair value of \$380,000 pursuant to a development agreement.

The Company incurred share issuance costs of \$557,936 related to the private placements.

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 14. SHARE CAPITAL (cont'd)

#### **Options**

Movements in the number of options outstanding and their related weighted average exercise prices are as follows:

| are as removes.                |                   |                                 |
|--------------------------------|-------------------|---------------------------------|
|                                | Number of options | Weighted average exercise price |
|                                |                   | \$                              |
| Outstanding, December 31, 2021 | 7,690,000         | 0.42                            |
| Granted                        | 430,000           | 0.20                            |
| Granted Under Debenture        | 12,754,000        | 0.15                            |
| Forfeited                      | -330,000          | 0.41                            |
| Outstanding, June 30, 2022     | 20,544,000        | \$ 0.25                         |
| •                              |                   |                                 |
|                                | Number of options | Weighted average exercise price |
|                                | -                 | \$                              |
| Outstanding, December 31, 2020 |                   | -                               |
| Granted                        | 3,050,000         | 0.30                            |
| Granted                        | 4,525,000         | 0.50                            |
| Granted                        | 105,000           | 0.60                            |
| Granieu                        | 105,000           | 0.00                            |
| Granted                        | 10,000            | 0.67                            |

The fair value of each tranche is measured at the date of grant using the Black-Scholes option pricing model.

Weighted average of option model inputs and fair value for options granted during the six months ended June 30, 2022 were as follows:

| Options     | Share | Exercise | Risk-free     | Expected | Volatility | Fair Value |
|-------------|-------|----------|---------------|----------|------------|------------|
| Options     | Price | Price    | Interest Rate | Life     | Factor     | Per Option |
| #           | \$    | \$       | %             | (years)  | %          | \$         |
| <br>430,000 | 0.20  | 0.20     | 0.10%         | 5        | 150%       | 0.18       |

The following summarizes information about the outstanding stock options exercisable to acquire common shares of the Company as at June 30, 2022 and December 31, 2021:

#### June 30, 2022:

|           | Weighted average remaining contractual life | Weighted average exercise price |
|-----------|---|---------------------------------|
| #         | (years)                                     | \$                              |
| 7,730,000 | 3.91  | 0.41                            |

#### December 31, 2021:

|           | Weighted average remaining contractual life | Weighted average exercise price |
|-----------|---|---------------------------------|
| #         | (years)                                     | \$_                             |
| 7,690,000 | 4.38  | 0.42                            |

As of June 30, 2022, 2,785,000 stock options had vested (December 31, 2021 - nil).

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 14. SHARE CAPITAL (cont'd)

Movements in the number of restricted stock units outstanding and their related weighted average exercise prices are as follows:

|                                | Units     | Weighted average exercise price |
|--------------------------------|-----------|---------------------------------|
|                                | #         | . \$_                           |
| Outstanding, December 31, 2021 | 1,500,000 | -                               |
| Granted                        | 130,000   | -                               |
| Outstanding, June 30, 2022     | 1,630,000 |                                 |
|                                | #         | \$                              |
| Outstanding, December 31, 2020 | -         | -                               |
| Granted                        | 1,500,000 | -                               |
| Outstanding, December 31, 2021 | 1,500,000 | -                               |

#### Restricted stock units

The following summarizes information about the outstanding restricted stock units exercisable to acquire common shares of the Company as at June 30, 2022 and December 31, 2021:

June 30, 2022:

| Outstanding                       |  |   | Exercisable       |   |   |
|-----------------------------------|--|---|-------------------|---|---|
| Number of units                   | Weighted average<br>remaining<br>contractual life<br>(years) | Weighted<br>average<br>exercise price<br>\$ | Number of options | Weighted average remaining contractual life (years) | Weighted<br>average<br>exercise price<br>\$ |
| 1,630,000                         | 4.08   |   | 1,125,000         | 4.08  |   |
| December 31, 2021:<br>Outstanding |  |   | Exercisable       |   |   |
| Number of units                   | Weighted average<br>remaining<br>contractual life<br>(years) | Weighted average exercise price \$          | Number of units   | Weighted average remaining contractual life (years) | Weighted<br>average<br>exercise price<br>\$ |
| 1,500,000                         | 4.53   | -   | 375,000           | 4.53  | -   |

#### **Warrants**

Warrants entitle the holder thereof to acquire one common share. No fractional shares are issuable upon the exercise of warrants. The Company may either pay a cash amount or round up to the nearest whole share in such circumstances. Warrants do not have any voting or pre-emptive rights or any other rights which a holder of common shares would have.

The following is a schedule of the warrants outstanding as at June 30, 2022 and December 31, 2021:

|                                | Number of<br>warrants | Weighted average remaining contractual life | Weighted average exercise price |
|--------------------------------|-----------------------|---|---------------------------------|
|                                |                       | (years)                                     | \$                              |
| Outstanding, December 31, 2021 | 5,732,143             | 4.63  | 0.68                            |
| Issued under Debenture         | 12,754,000            | 2.80  | .20                             |
| Outstanding, June 30, 2022     | 18,486,143            | 4.29  | 0.35                            |

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

|                                | Number of warrants | Weighted average<br>remaining contractual life<br>(years) | Weighted average<br>exercise price<br>\$ |
|--------------------------------|--------------------|---|--|
| Outstanding, December 31, 2020 | -                  | -   | -  |
| Granted                        | 5,732,143          | 5.00  | 0.68                                     |
| Outstanding, December 31, 2021 | 5,732,143          | 4.88  | 0.68                                     |

#### 15. FINANCIAL INSTRUMENTS AND RISKS

#### Fair values

Assets and liabilities measured at fair value on a recurring basis were presented on the Company's statement of financial position as at June 30, 2022 and December 31, 2021, as follows:

|      |                | June 30, 2022 |                  |         |  |
|------|----------------|---------------|------------------|---------|--|
|      | Carrying value | Level 1       | Level 2          | Level 3 |  |
|      | \$             | \$            | \$               | \$      |  |
| Cash | 803,245        | 803,245       | -                | -       |  |
|      |                | D             | ecember 31, 2021 |         |  |
|      | Carrying value | Level 1       | Level 2          | Level 3 |  |
|      | \$             | \$            | \$               | \$      |  |
| Cash | 3,886,851      | 3,886,851     | -                | -       |  |

The fair values of other financial instruments, which include amounts receivable, prepaid and deposits, amounts payable and lease liabilities approximate, approximate their carrying values due to the relatively short-term maturity of these instruments.

The fair value of acquisition consideration payable was determined using a present value of a probability weighted average of expected future cash outflows.

All financial instruments measured at fair value use Level 2 valuation techniques. There have been no transfers between fair value levels during the reporting period.

The Company's financial instruments are exposed to certain financial risks, including credit, liquidity, currency, and interest rate risk.

#### Credit risk

Credit risk arises from cash held with banks and financial institutions, as well as credit exposure on any outstanding accounts receivable. The carrying amount of financial assets represents the maximum credit exposure.

#### **Currency risk**

Currency risk is the risk that changes in foreign exchange rates will affect the Company's income or the value of its holdings of financial instruments. The Company's currency risk primarily arises from financial instruments denominated in currencies other than its functional currency. The Company does not undertake currency hedging activities to mitigate its foreign currency risk. The impact on the Company's profit or loss resulting from a 10% fluctuation in foreign exchange rates would be approximately \$232,000.

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 15. FINANCIAL INSTRUMENTS AND RISKS (cont'd)

#### Interest rate risk

Interest rate risk consists of two components:

- (i) To the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk.
- (ii) To the extent that changes in prevailing market rates differ from the interest rate in the Company's monetary assets and liabilities, the Company is exposed to interest rate price risk.

Current financial assets and financial liabilities are generally not exposed to interest rate risk because of their short-term nature and maturity. The Company's amounts due to related parties are non-interest bearing.

#### Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles its financial obligations out of cash. The ability to do this relies on the Company raising equity financing in a timely manner and by maintaining sufficient cash in excess of anticipated needs.

June 30, 2022

|  | Total      | Less than 1 year | 1 to 3 years | 3 to 5 years | Over 5 years |
|--|------------|------------------|--------------|--------------|--------------|
|  | \$         | \$               | \$           | \$           | \$           |
| Accounts payable and accrued liabilities | 415,083    | 415,083          | -            | _            | -            |
| Lease obligations                        | 8,775,388  | 1,956,636        | 3,524,842    | 2,064,442    | 1,229,468    |
|  |            |                  |              |              | _            |
|  | 9,190,471  | 2,371,719        | 3,524,844    | 2,064,442    | 1,229,468    |
| December 21, 2021                        |            |                  |              |              |              |
| December 31, 2021                        | T . 4 . 1  | 1 41 4           | 4.10         | 0.1. 5       | 0            |
|  | Total      | Less than 1 year | 1 to 3 years | 3 to 5 years | Over 5 years |
|  | \$         | \$               | \$           | \$           | \$           |
| Accounts payable and accrued liabilities | 686,674    | 686,674          | -            | -            | -            |
| Share consideration payable              | 1,916,556  | 1,916,556        | -            | -            | -            |
| Lease obligations                        | 8,775,381  | 1,598,965        | 3,459,881    | 2,777,308    | 1,330,574    |
|  | 11,769,958 | 4,202,195        | 3,459,881    | 2,777,308    | 1,330,574    |

#### 16. CAPITAL MANAGEMENT

The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of all components of shareholders' equity.

The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board of Directors, will balance its overall capital structure through new share issuances or by undertaking other activities, as deemed appropriate under the specific circumstances.

The Company is not subject to externally imposed capital requirements and the Company's overall strategy with respect to capital risk management remains unchanged from the year ended December 31, 2021.

Notes to the unaudited condensed interim consolidated financial statements For the six months ended June 30, 2022 and 2021 (expressed in Canadian dollars)

#### 17. SEGMENT REPORTING

Information reported to the Chief Operating Decision Maker ("CODM") for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in three segments:

Clinical Operations: which encompass the Company's ketamine assisted psychotherapy clinics across the United States of America.

Research: which consists of the development of virtual clinics in the metaverse and research focused expenses.

Corporate: which incorporates the operations of Revitalist's headquarters.

Factors considered in determining the operating segments include the company's business activities, the management structure directly accountable to the CODM, availability of discrete financial information and strategic priorities within the organizational structure.

Six months ended June 30, 2022:

| Segment Information | Clinical Operations | Research  | Corporate   | Total       |
|---------------------|---------------------|-----------|-------------|-------------|
|                     | \$                  | \$        | \$          | \$          |
| Net revenue         | 2,435,920           | -         | -           | 2,435,920   |
| Net income (loss)   | (1,269,842)         | (150,403) | (3,364,735) | (7,977,001) |

six months ended June 30, 2021:

| Segment Information | Clinical Operations | Research | Corporate   | Total       |
|---------------------|---------------------|----------|-------------|-------------|
|                     | \$                  | \$       | \$          | \$          |
| Net revenue         | 148,985             | -        | -           | 148,985     |
| Net income (loss)   | 51,837              | -        | (3,776,229) | (3,724,392) |

#### 18. CONTINGENCY

On November 5, 2021, the Company was named in a lawsuit initiated by an industry competitor seeking damages of an unspecified amount. Revitalist denies any liability and has filed a counterclaim seeking damages from the plaintiff. The outcome of the lawsuit is undeterminable, and no amount has been recorded in the consolidated financial statements.

#### 19. SUBSEQUENT EVENT